Stonepine Capital Management LLC Grows Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Stonepine Capital Management LLC boosted its stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 27.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,458,873 shares of the biotechnology company’s stock after purchasing an additional 531,427 shares during the period. Aclaris Therapeutics comprises about 1.8% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 19th biggest position. Stonepine Capital Management LLC owned approximately 3.44% of Aclaris Therapeutics worth $2,828,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently bought and sold shares of ACRS. SG Americas Securities LLC boosted its position in shares of Aclaris Therapeutics by 69.5% during the first quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 13,461 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Aclaris Therapeutics by 5,265.1% during the 1st quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 61,602 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Aclaris Therapeutics by 4.4% during the first quarter. Vanguard Group Inc. now owns 4,929,775 shares of the biotechnology company’s stock valued at $6,113,000 after purchasing an additional 207,418 shares in the last quarter. Trium Capital LLP bought a new stake in shares of Aclaris Therapeutics in the second quarter worth about $2,081,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Aclaris Therapeutics in the second quarter worth about $119,000. 98.34% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Aclaris Therapeutics

In other Aclaris Therapeutics news, Director Anand Mehra bought 666,666 shares of Aclaris Therapeutics stock in a transaction that occurred on Tuesday, November 19th. The shares were bought at an average cost of $2.25 per share, with a total value of $1,499,998.50. Following the transaction, the director now directly owns 710,030 shares of the company’s stock, valued at approximately $1,597,567.50. This represents a 1,537.37 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 6.40% of the company’s stock.

Aclaris Therapeutics Trading Up 2.5 %

Shares of NASDAQ:ACRS traded up $0.09 during trading hours on Wednesday, hitting $3.72. The company’s stock had a trading volume of 74,855 shares, compared to its average volume of 1,412,578. The firm’s fifty day moving average price is $1.87 and its 200 day moving average price is $1.43. Aclaris Therapeutics, Inc. has a 52 week low of $0.80 and a 52 week high of $5.17.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.03). Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%. The company had revenue of $4.35 million for the quarter, compared to the consensus estimate of $8.31 million. Equities analysts anticipate that Aclaris Therapeutics, Inc. will post -0.75 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ACRS shares. Piper Sandler raised shares of Aclaris Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $3.00 to $13.00 in a research note on Monday, November 18th. Leerink Partners upgraded Aclaris Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $2.00 to $7.00 in a research report on Tuesday, November 19th. HC Wainwright restated a “neutral” rating on shares of Aclaris Therapeutics in a research report on Tuesday, September 17th. Leerink Partnrs upgraded Aclaris Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 19th. Finally, StockNews.com upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $8.80.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.